MARKET

VTGN

VTGN

Vistagen Therapeutics Inc
NASDAQ
0.1177
-0.0013
-1.09%
Opening 13:26 12/09 EST
OPEN
0.1188
PREV CLOSE
0.1190
HIGH
0.1251
LOW
0.1151
VOLUME
1.81M
TURNOVER
123.80K
52 WEEK HIGH
2.110
52 WEEK LOW
0.0768
MARKET CAP
24.34M
P/E (TTM)
-0.3746
1D
5D
1M
3M
1Y
5Y
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 3d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 3d ago
Vistagen Receives FDA Fast Track Designation For Development Of PH10 To Treat Major Depressive Disorder
Benzinga · 3d ago
VistaGen Nasal Spray for Major Depressive Disorder Granted FDA's Fast Track Designation
VistaGen Nasal Spray for Major Depressive Disorder Granted FDA's Fast Track Designation
MT Newswires · 3d ago
BRIEF-Vistagen Receives FDA “Study May Proceed” Letter Under Its Investigational New Drug Application For Ph10 To Treat Major Depressive Disorder
Reuters · 11/30 13:33
VistaGen Therapeutics Gets US FDA Clearance to Conduct Phase 1 Trial for Potential Major Depressive Disorder Treatment
VistaGen Therapeutics Gets US FDA Clearance to Conduct Phase 1 Trial for Potential Major Depressive Disorder Treatment
MT Newswires · 11/30 11:02
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 11/29 21:32
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 11/23 21:32
More
About VTGN
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its pipeline includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that is preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that is planning for Phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. Its AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), which is a potent and selective full antagonist of the glycine co-agonist site of the N-methyl-D-aspartate receptor (NMDAR) that inhibits the function of the NMDAR, an ionotropic glutamate receptor in the brain.

Webull offers kinds of Vistagen Therapeutics Inc stock information, including NASDAQ:VTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTGN stock methods without spending real money on the virtual paper trading platform.